Early HTA scientific advice reduces price and reimbursement risk by informing ev...
Read moreWhile missing an EU Joint Scientific Consultation (JSC) is suboptimal, the greater strategic concern...
Read moreThe increasing complexity of bringing innovative therapies to market across various jurisdictions pr...
Read moreRemap Consulting presents ground-breaking insights and practical learnings from one of the pioneerin...
Read moreWe're delighted to announce our participation at ISPOR Europe 2024 in Barcelona this November. We'll...
Read moreOur latest article discusses key strategies for pharma manufacturers' commercial readiness for EU HT...
Read moreWe summarise the key discussions from HTAi 2024, with a focus on sustainability, networks and innova...
Read moreWe discuss the updates on EU HTA from the June meeting of the Member State Coordination Group on Hea...
Read moreLearn how to navigate the upcoming EU HTA regulation and optimise market access strategies for oncol...
Read moreBack in January this year, we summarised the key trends our market access experts believed would dom...
Read more